Correction to: J Exp Clin Cancer Res 40, 23 (2021)
https://doi.org/10.1186/s13046-020-01821-6
Following publication of the original article [1], the authors identified minor errors in image-typesetting in Fig. 1; specifically in panels presented in Fig 1c, d, f and g. The corrected figure and caption are given below.
ACTN1 is highly expressed in HCC tissues and predicts a poor prognosis in HCC patients. a The mRNA expression level of ACTN1 in 20 paired HCC and NCL tissues was analyzed by real-time qPCR. b The protein expression level of ACTN1 in 5 paired HCC and NCL tissues. c Representative immunohistochemical images of ACTN1 in HCC, thrombus, NCL and normal liver tissues. Scale bar: 50 μm. d Immunohistochemical staining of ACTN1 in a tissue microarray containing 157 cases of HCC samples. Scale bar: 50 μm. e The expression of ACTN1 was up-regulated in 74% of HCC patients. f-g Kaplan-Meier curve analysis of overall survival (OS) and disease-free survival (DFS) in HCC patients based on the expression of ACTN1. h Kaplan-Meier curve analysis of OS in TCGA cohort based on the expression of ACTN1. **P < 0.01
In addition, sections of the mainbody text have been corrected in light of the above. In the ‘Results’ section, under the heading ‘Highly expressed ACTN1 predicts a poor clinical outcome in HCC patients’, the following sentences have been corrected (emphasis given to affected areas):
“Immunohistochemical analysis showed that ACTN1 was highly expressed in 69.4% (132/157) of HCC patients (Fig. 1d and e).” has been corrected to: “Immunohistochemical analysis showed that ACTN1 was highly expressed in 74% (116/157) of HCC patients (Fig. 1d and e).
“As displayed in Fig. 1f, high expression of ACTN1 was positively correlated with poor overall survival (OS, P = 0.027) in HCC.” Has been corrected to: “As displayed in Fig. 1f, high expression of ACTN1 was positively correlated with poor overall survival (OS, P = 0.007) in HCC.”
The correction does not have any effect on the results or conclusions of the paper. The original article has been corrected.
Reference
Chen Q, Zhou XW, Zhang AJ, et al. ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. J Exp Clin Cancer Res. 2021;40:23 https://doi.org/10.1186/s13046-020-01821-6.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Chen, Q., Zhou, XW., Zhang, AJ. et al. Correction to: ACTN1 supports tumor growth by inhibiting Hippo signaling in hepatocellular carcinoma. J Exp Clin Cancer Res 40, 128 (2021). https://doi.org/10.1186/s13046-021-01924-8
Published:
DOI: https://doi.org/10.1186/s13046-021-01924-8